Literature DB >> 18338210

Appraisal of hepatic resection in the treatment of hepatocellular carcinoma with severe thrombocytopenia.

Keishi Sugimachi1, Yasuharu Ikeda, Morimasa Tomikawa, Akinobu Taketomi, Shuichi Tsukamoto, Katsumi Kawasaki, Shinji Yamamura, Daisuke Korenaga, Yoshihiko Maehara, Kenji Takenaka.   

Abstract

BACKGROUND: Hepatic resection for hepatocellular carcinoma (HCC) patients with liver cirrhosis and severe hypersplenic thrombocytopenia is risky and controversial.
METHODS: From 1989 to 2005, 341 patients underwent hepatic resection for HCC in our hospital. Of these, 15 patients were concomitant with severe thrombocytopenia (platelet count, <or=5 x 10(4)/mm(3)), and their clinical outcomes were retrospectively reviewed.
RESULTS: Among the 15 patients, 11 underwent hepatectomy alone and 4 underwent concomitant splenectomy. The mean preoperative platelet count was 4.2 +/- 0.8 x 10(4)/mm(3) (range, 1.9-5 x 10(4)/mm(3)). The surgical procedures performed were partial resection in five patients, subsegmentectomy in three, and segmentectomy in seven. A blood transfusion was required for 11 of 15 patients, and 8 of these received a platelet-rich plasma transfusion. With the exception of one patient who suffered from postoperative liver failure, all the patients had an uneventful postoperative course. The 3-year cumulative survival rate of these patients was comparable to those without thrombocytopenia.
CONCLUSIONS: Severe thrombocytopenia alone is not a contraindication for hepatectomy in patients with HCC associated with liver cirrhosis. For these patients, hepatic resection-hepatectomy alone or concomitant splenectomy-should be considered as a treatment option.

Entities:  

Mesh:

Year:  2008        PMID: 18338210     DOI: 10.1007/s00268-007-9442-3

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  17 in total

1.  Splenectomy in patients with hepatocellular carcinoma and hypersplenism.

Authors:  Y Sugawara; J Yamamoto; K Shimada; S Yamasaki; T Kosuge; T Takayama; M Makuuchi
Journal:  J Am Coll Surg       Date:  2000-04       Impact factor: 6.113

2.  Surgery for cirrhotic patients with hepatocellular carcinoma and hypersplenism.

Authors:  K J Paquet
Journal:  Surg Endosc       Date:  2001-01       Impact factor: 4.584

3.  Assessment of hepatic reserve for the indication of hepatic resection.

Authors:  Jaques Belghiti; Satoshi Ogata
Journal:  J Hepatobiliary Pancreat Surg       Date:  2005

Review 4.  Updated treatment approach to hepatocellular carcinoma.

Authors:  Josep M Llovet
Journal:  J Gastroenterol       Date:  2005-03       Impact factor: 7.527

5.  Report of the 16th follow-up survey of primary liver cancer.

Authors:  Iwao Ikai; Shigeki Arii; Takafumi Ichida; Kiwamu Okita; Masao Omata; Masamichi Kojiro; Kenichi Takayasu; Yasuni Nakanuma; Masatoshi Makuuchi; Yutaka Matsuyama; Yoshio Yamaoka
Journal:  Hepatol Res       Date:  2005-07-18       Impact factor: 4.288

6.  Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test.

Authors:  Hiroshi Imamura; Keiji Sano; Yasuhiko Sugawara; Norihiko Kokudo; Masatoshi Makuuchi
Journal:  J Hepatobiliary Pancreat Surg       Date:  2005

Review 7.  The surgical approach to HCC: our progress and results in Japan.

Authors:  Masatoshi Makuuchi; Keiji Sano
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

8.  Effects of splenectomy in patients with cirrhosis undergoing hepatic resection for hepatocellular carcinoma.

Authors:  Zhi-Xin Cao; Xiao-Ping Chen; Zai-De Wu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

9.  The role of splenectomy in patients with hepatocellular carcinoma and secondary hypersplenism.

Authors:  Jae Won Oh; Soo Min Ahn; Kyung Sik Kim; Jin Sub Choi; Woo Jung Lee; Byung Ro Kim
Journal:  Yonsei Med J       Date:  2003-12-30       Impact factor: 2.759

10.  Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey.

Authors:  Iwao Ikai; Shigeki Arii; Masamichi Kojiro; Takafumi Ichida; Masatoshi Makuuchi; Yutaka Matsuyama; Yasuni Nakanuma; Kiwamu Okita; Masao Omata; Kenichi Takayasu; Yoshio Yamaoka
Journal:  Cancer       Date:  2004-08-15       Impact factor: 6.860

View more
  6 in total

Review 1.  Management before hepatectomy for hepatocellular carcinoma with cirrhosis.

Authors:  Hisashi Nakayama; Tadatoshi Takayama
Journal:  World J Hepatol       Date:  2015-09-18

2.  Importance of low preoperative platelet count in selecting patients for resection of hepatocellular carcinoma: a multi-institutional analysis.

Authors:  Shishir K Maithel; Peter J Kneuertz; David A Kooby; Charles R Scoggins; Sharon M Weber; Robert C G Martin; Kelly M McMasters; Clifford S Cho; Emily R Winslow; William C Wood; Charles A Staley
Journal:  J Am Coll Surg       Date:  2011-04       Impact factor: 6.113

3.  Low immediate postoperative platelet count is associated with hepatic insufficiency after hepatectomy.

Authors:  Hai-Qing Wang; Jian Yang; Jia-Yin Yang; Wen-Tao Wang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 4.  Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients.

Authors:  Alessandro Cucchetti; Matteo Cescon; Franco Trevisani; Antonio Daniele Pinna
Journal:  World J Gastroenterol       Date:  2012-11-28       Impact factor: 5.742

5.  Simultaneous hepatectomy and splenectomy versus hepatectomy alone for hepatocellular carcinoma complicated by hypersplenism: a meta-analysis.

Authors:  Wei Li; Shi-Qiang Shen; Shan-Min Wu; Zu-Bing Chen; Chao Hu; Rui-Chen Yan
Journal:  Onco Targets Ther       Date:  2015-08-19       Impact factor: 4.147

6.  Synchronous splenectomy and hepatectomy for patients with small hepatocellular carcinoma and pathological spleen: neutrophil to lymphocyte ratio changes can predict the prognosis.

Authors:  Xiaoyun Zhang; Chuan Li; Tianfu Wen; Wei Peng; Lunan Yan; Bo Li; Jiayin Yang; Wentao Wang; Mingqing Xu; Yong Zeng
Journal:  Oncotarget       Date:  2017-07-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.